Abstract: Global Active Pharmaceutical Ingredients (API) Market to Reach US$265. 3 Billion by the Year 2026 . APIs represent biologically-active substances and primary components for drug manufacturing.
New York, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Active Pharmaceutical Ingredients (API) Industry" - https://www.reportlinker.com/p06219466/?utm_source=GNW
The production of APIs globally is mainly concentrated to developing nations due to their capability to scale production as per customization and low-cost manufacturing. The API market is slated to gain from increasing focus on generic and branded drugs as a result of rising prevalence of non-communicable and chronic medical conditions due to lifestyle changes and rapid urbanization. The market growth is anticipated to be augmented further from the transition away from conventional manufacturing techniques, rising investment in drug discovery, and strong adherence to product quality. The market is also benefitting from increasing influx of generic drugs that are produced following permission of a pharmaceutical company for creating the own version of the medicine. The COVID-19 pandemic and the resulting disruptions in supply chain are driving various governments to boycott sourcing of APIs from China. Despite these challenges, the API market is bound to progress ahead swiftly due to positive factors like pending approval of various generic and blockbuster drugs that rely on APIs.
Amid the COVID-19 crisis, the global market for Active Pharmaceutical Ingredients (API) estimated at US$177.5 Billion in the year 2020, is projected to reach a revised size of US$265.3 Billion by 2026, growing at a CAGR of 6.7% over the analysis period. Innovative, one of the segments analyzed in the report, is projected to grow at a 6.4% CAGR to reach US$190.9 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Generic segment is readjusted to a revised 7.4% CAGR for the next 7-year period. This segment currently accounts for a 30.2% share of the global Active Pharmaceutical Ingredients (API) market. As patents for branded APIs expire, opportunities for generic APIs increase, resulting in an augmented API market demand.
The U.S. Market is Estimated at $71.5 Billion in 2021, While China is Forecast to Reach $35.4 Billion by 2026
The Active Pharmaceutical Ingredients (API) market in the U.S. is estimated at US$71.5 Billion in the year 2021. The country currently accounts for a 36.3% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$35.4 Billion in the year 2026 trailing a CAGR of 7.6% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.1% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR while Rest of European market (as defined in the study) will reach US$37.5 Billion by the end of the analysis period. China is a leading producer and exporter of APIs, accounting for about 20% of global API production. The country`s strong presence in API production could be attributed to factors such as low cost of utilities and strong government support. COVID-19 has highlighted various vulnerabilities associated with sourcing of APIs from other regions or countries, such as fractured supply chain and limited scope for immediate response to changes. These challenges are now prompting a number of European nations and the US to focus on relocation of pharmaceutical and API production back to home country.
Select Competitors (Total 266 Featured)
-
AbbVie Inc.
-
Aurobindo Pharma Ltd.
-
BASF SE
-
Boehringer Ingelheim International GmbH
-
Cipla Ltd.
-
Dr. Reddy’s Laboratories Ltd.
-
Lupin Ltd.
-
Merck KGaA
-
Novartis International AG
-
Pfizer Inc.
-
Sun Pharmaceutical Industries Ltd.
-
Teva Pharmaceutical Industries Ltd.
-
Viatris Inc.
Read the full report: https://www.reportlinker.com/p06219466/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
2020: A Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is
the World Economy Headed in 2021
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual %
Change) for 2020 through 2022
COVID-19 Alters Pharmaceutical Industry and API Production
Dynamics
COVID-19 Exposes US Pharmaceutical Makers to Risk of Supply
Shortages, Driving the Need to Revamp Domestic Industry
Structure
Pandemic Leads US to Focus on Stockpiling & Localized
Manufacturing to Rectify Supply Chain Flaws
EXHIBIT 2: Percentage Breakdown of API Manufacturing Facilities
by Country for Drug Production in the US: 2020
Revamping Local Production Capacity
Knock-on Effect of COVID-19 on API Availability Incites Players
to Reconfigure Supply Chain
COVID-19 Pandemic: A Wake-Up Call for API Seekers to Mitigate
Supply Risks
Short-Term Strategies
Long-Term Strategies
Unprecedented Global Push to Expedite COVID-19 Vaccine
Development to Spur Demand for APIs
EXHIBIT 3: Global Percentage of Individuals Vaccinated by
Geographic Region for 2020 through 2025
EXHIBIT 4: Number of CMO Sites for Vaccine Production in Select
Countries: 2020
Active Pharmaceutical Ingredients: A Prelude
Outlook
Regional Landscape
US CDMOs to Gain from Mounting Concerns Over Excess Reliance On
Chinese APIs
China Continues to Remain a Major Hub
COVID-19 Brings Europe?s High Reliance on APIs Sourced from
Outside under Spotlight
India Strives to Increase API Production to Attain Self
Reliance in Pharmaceutical Production
EXHIBIT 5: Domestic Production and Import Share of Select API/
Advanced Intermediates in India: 2019
Global PE Firms to Invest Heavily in Indian Intermediate Pharma
Companies
Recent Market Activity
world Brands
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Sustained Increase in Drug R&D Spending to Drive API Market
EXHIBIT 6: Pharmaceutical R&D Spending Worldwide (USD Billion):
2015-2025
Increased API Sourcing Creates the need for More Scrutiny of
Suppliers for Best Quality Products
Preference for Specialized CDMO Contractors on the Rise
Strong Rise in Pharmaceutical Sales to Drive Demand
EXHIBIT 7: Global Prescription Drug Sales (In US$ Billion) for
the Years 2017, 2019, 2021, 2023 & 2025
The AIC Approach for Faster Assessment of Viable Drug Candidates
Drug Makers Embrace Digital Technology Amidst COVID-19 Crisis
EXHIBIT 8: Digital Transformation Spending in US$ Billion in
Pharma Sector: 2020 and 2027
AI Finds Growing Application in Drug Discovery and Development
Microdosing Beneficial for the Formulation of High Potency
Ingredients
Growing Penetration of Generic Drugs Augments Market Prospects
EXHIBIT 9: Leading Drugs Facing Patent Expiry in the US in 2020
EXHIBIT 10: Global Generic Drugs Market Size (in $ Billion) for
the Years 2016, 2019, 2020 & 2025
Increasing Interest in Biopharmaceuticals Supports Market Demand
EXHIBIT 11: Global Biologic Drugs Market Size (in US$ Billion)
for the Years 2019, 2022 & 2025
Rising Number of Biologics Approvals Augurs Well
EXHIBIT 12: The U.S FDA Biologic NME Approvals for Years 2016
through 2020
EXHIBIT 13: Sponsor Market Cap for the FDA-Approved Biologic
FDA NMEs (2020)
Growing Biosimilars Market Create Opportunities for APIs
EXHIBIT 14: Global Biosimilars Market in US$ Billion: 2020 & 2025
Growing Attention Towards Personalized Medicine Spurs Demand
for Complex API
EXHIBIT 15: Global Personalized Medicine Market: Revenues in
US$ Million for the Years 2019, 2021, 2023 and 2025
Increasing Sales of OTC Drugs Presents an Opportunity for APIs
EXHIBIT 16: Global OTC Drugs Market Breakdown by Product
(in %): 2020E
Growing Prevalence of Infectious Diseases to Spur Growth
EXHIBIT 17: Infectious Diseases Remain Major Cause of Death in
Under Developed Regions: Breakdown of Leading Causes of Death
in Sub-Saharan Africa (in %)
EXHIBIT 18: Global Number of Deaths Caused Due to Communicable
Diseases (In 000s)
Rising Incidence of Cancer & Need to Reduce Cancer-Related
Mortality Spell Increased Demand
EXHIBIT 19: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 20: Global Breakdown of Total Number of Cancer Cases by
Type: 2020
Increasing Prevalence of Chronic Disorders Fuels Market Growth
EXHIBIT 21: World Diabetes and Population Statistics (2019,
2030 & 2045)
Rising Incidence of Cardiovascular Diseases Revs Up Opportunities
EXHIBIT 22: Hypertension Prevalence (%) Worldwide by Region in
Male and Females Aged 25+ Years
EXHIBIT 23: Fatalities by Heart Conditions: Estimated
Percentage Breakdown for Cardiovascular Disease, Ischemic
Heart Disease, Stroke, and Others
Upsurge in ANDA Approvals Bodes Well
Aging Population & Increasing Burden of Chronic Diseases Spurs
Pharma Product Sales, Driving Market Growth
EXHIBIT 24: Global Aging Population Statistics for the 65+ Age
Group in Million by Geographic Region for the Years 2019,
2025, 2035 and 2050
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Active Pharmaceutical
Ingredients (API) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets for Years 2012, 2021 &
2027
Table 4: World Current & Future Analysis for Innovative by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 5: World Historic Review for Innovative by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 6: World 15-Year Perspective for Innovative by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027
Table 7: World Current & Future Analysis for Generic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 8: World Historic Review for Generic by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Generic by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027
Table 10: World Current & Future Analysis for Synthetic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 11: World Historic Review for Synthetic by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Synthetic by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027
Table 13: World Current & Future Analysis for Biotech by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 14: World Historic Review for Biotech by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Biotech by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027
Table 16: World Current & Future Analysis for Cardiovascular
Diseases by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 17: World Historic Review for Cardiovascular Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 18: World 15-Year Perspective for Cardiovascular Diseases
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 19: World Current & Future Analysis for Endocrinology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 20: World Historic Review for Endocrinology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Endocrinology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 22: World Current & Future Analysis for CNS & Neurology
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 23: World Historic Review for CNS & Neurology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 24: World 15-Year Perspective for CNS & Neurology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 25: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 26: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 27: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027
Table 28: World Current & Future Analysis for Gastroenterology
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 29: World Historic Review for Gastroenterology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 30: World 15-Year Perspective for Gastroenterology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 31: World Current & Future Analysis for Orthopedic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 32: World Historic Review for Orthopedic by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 33: World 15-Year Perspective for Orthopedic by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 34: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 35: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 36: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Table 37: USA Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Type - Innovative and
Generic - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 38: USA Historic Review for Active Pharmaceutical
Ingredients (API) by Type - Innovative and Generic Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 39: USA 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Type - Percentage Breakdown of Value Sales
for Innovative and Generic for the Years 2012, 2021 & 2027
Table 40: USA Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Synthesis - Synthetic and
Biotech - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 41: USA Historic Review for Active Pharmaceutical
Ingredients (API) by Synthesis - Synthetic and Biotech Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 42: USA 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Synthesis - Percentage Breakdown of Value
Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
Table 43: USA Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Application -
Cardiovascular Diseases, Endocrinology, CNS & Neurology,
Oncology, Gastroenterology, Orthopedic and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 44: USA Historic Review for Active Pharmaceutical
Ingredients (API) by Application - Cardiovascular Diseases,
Endocrinology, CNS & Neurology, Oncology, Gastroenterology,
Orthopedic and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 45: USA 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Application - Percentage Breakdown of
Value Sales for Cardiovascular Diseases, Endocrinology, CNS &
Neurology, Oncology, Gastroenterology, Orthopedic and Other
Applications for the Years 2012, 2021 & 2027
CANADA
Table 46: Canada Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Type - Innovative and
Generic - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 47: Canada Historic Review for Active Pharmaceutical
Ingredients (API) by Type - Innovative and Generic Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 48: Canada 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Type - Percentage Breakdown of Value Sales
for Innovative and Generic for the Years 2012, 2021 & 2027
Table 49: Canada Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Synthesis - Synthetic and
Biotech - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 50: Canada Historic Review for Active Pharmaceutical
Ingredients (API) by Synthesis - Synthetic and Biotech Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 51: Canada 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Synthesis - Percentage Breakdown of Value
Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
Table 52: Canada Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Application -
Cardiovascular Diseases, Endocrinology, CNS & Neurology,
Oncology, Gastroenterology, Orthopedic and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 53: Canada Historic Review for Active Pharmaceutical
Ingredients (API) by Application - Cardiovascular Diseases,
Endocrinology, CNS & Neurology, Oncology, Gastroenterology,
Orthopedic and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 54: Canada 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Application - Percentage Breakdown of
Value Sales for Cardiovascular Diseases, Endocrinology, CNS &
Neurology, Oncology, Gastroenterology, Orthopedic and Other
Applications for the Years 2012, 2021 & 2027
JAPAN
Table 55: Japan Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Type - Innovative and
Generic - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 56: Japan Historic Review for Active Pharmaceutical
Ingredients (API) by Type - Innovative and Generic Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 57: Japan 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Type - Percentage Breakdown of Value Sales
for Innovative and Generic for the Years 2012, 2021 & 2027
Table 58: Japan Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Synthesis - Synthetic and
Biotech - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 59: Japan Historic Review for Active Pharmaceutical
Ingredients (API) by Synthesis - Synthetic and Biotech Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 60: Japan 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Synthesis - Percentage Breakdown of Value
Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
Table 61: Japan Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Application -
Cardiovascular Diseases, Endocrinology, CNS & Neurology,
Oncology, Gastroenterology, Orthopedic and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 62: Japan Historic Review for Active Pharmaceutical
Ingredients (API) by Application - Cardiovascular Diseases,
Endocrinology, CNS & Neurology, Oncology, Gastroenterology,
Orthopedic and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 63: Japan 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Application - Percentage Breakdown of
Value Sales for Cardiovascular Diseases, Endocrinology, CNS &
Neurology, Oncology, Gastroenterology, Orthopedic and Other
Applications for the Years 2012, 2021 & 2027
CHINA
Table 64: China Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Type - Innovative and
Generic - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 65: China Historic Review for Active Pharmaceutical
Ingredients (API) by Type - Innovative and Generic Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 66: China 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Type - Percentage Breakdown of Value Sales
for Innovative and Generic for the Years 2012, 2021 & 2027
Table 67: China Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Synthesis - Synthetic and
Biotech - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 68: China Historic Review for Active Pharmaceutical
Ingredients (API) by Synthesis - Synthetic and Biotech Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 69: China 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Synthesis - Percentage Breakdown of Value
Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
Table 70: China Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Application -
Cardiovascular Diseases, Endocrinology, CNS & Neurology,
Oncology, Gastroenterology, Orthopedic and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 71: China Historic Review for Active Pharmaceutical
Ingredients (API) by Application - Cardiovascular Diseases,
Endocrinology, CNS & Neurology, Oncology, Gastroenterology,
Orthopedic and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 72: China 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Application - Percentage Breakdown of
Value Sales for Cardiovascular Diseases, Endocrinology, CNS &
Neurology, Oncology, Gastroenterology, Orthopedic and Other
Applications for the Years 2012, 2021 & 2027
EUROPE
Table 73: Europe Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 74: Europe Historic Review for Active Pharmaceutical
Ingredients (API) by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR
Table 75: Europe 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Geographic Region - Percentage Breakdown
of Value Sales for France, Germany, Italy, UK and Rest of
Europe Markets for Years 2012, 2021 & 2027
Table 76: Europe Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Type - Innovative and
Generic - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 77: Europe Historic Review for Active Pharmaceutical
Ingredients (API) by Type - Innovative and Generic Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 78: Europe 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Type - Percentage Breakdown of Value Sales
for Innovative and Generic for the Years 2012, 2021 & 2027
Table 79: Europe Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Synthesis - Synthetic and
Biotech - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 80: Europe Historic Review for Active Pharmaceutical
Ingredients (API) by Synthesis - Synthetic and Biotech Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 81: Europe 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Synthesis - Percentage Breakdown of Value
Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
Table 82: Europe Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Application -
Cardiovascular Diseases, Endocrinology, CNS & Neurology,
Oncology, Gastroenterology, Orthopedic and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 83: Europe Historic Review for Active Pharmaceutical
Ingredients (API) by Application - Cardiovascular Diseases,
Endocrinology, CNS & Neurology, Oncology, Gastroenterology,
Orthopedic and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 84: Europe 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Application - Percentage Breakdown of
Value Sales for Cardiovascular Diseases, Endocrinology, CNS &
Neurology, Oncology, Gastroenterology, Orthopedic and Other
Applications for the Years 2012, 2021 & 2027
FRANCE
Table 85: France Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Type - Innovative and
Generic - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 86: France Historic Review for Active Pharmaceutical
Ingredients (API) by Type - Innovative and Generic Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 87: France 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Type - Percentage Breakdown of Value Sales
for Innovative and Generic for the Years 2012, 2021 & 2027
Table 88: France Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Synthesis - Synthetic and
Biotech - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR
Table 89: France Historic Review for Active Pharmaceutical
Ingredients (API) by Synthesis - Synthetic and Biotech Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 90: France 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Synthesis - Percentage Breakdown of Value
Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
Table 91: France Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Application -
Cardiovascular Diseases, Endocrinology, CNS & Neurology,
Oncology, Gastroenterology, Orthopedic and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 92: France Historic Review for Active Pharmaceutical
Ingredients (API) by Application - Cardiovascular Diseases,
Endocrinology, CNS & Neurology, Oncology, Gastroenterology,
Orthopedic and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 93: France 15-Year Perspective for Active Pharmaceutical
Ingredients (API) by Application - Percentage Breakdown of
Value Sales for Cardiovascular Diseases, Endocrinology, CNS &
Neurology, Oncology, Gastroenterology, Orthopedic and Other
Applications for the Years 2012, 2021 & 2027
GERMANY
Table 94: Germany Current & Future Analysis for Active
Pharmaceutical Ingredients (API) by Type - Innovative and
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06219466/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
"ingredients" - Google News
January 19, 2022 at 07:34PM
https://ift.tt/3fFuPHG
Global Active Pharmaceutical Ingredients (API) Market to Reach US$265.3 Billion by the Year 2026 - Yahoo Finance
"ingredients" - Google News
https://ift.tt/2Qstat1
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
Bagikan Berita Ini
0 Response to "Global Active Pharmaceutical Ingredients (API) Market to Reach US$265.3 Billion by the Year 2026 - Yahoo Finance"
Post a Comment